# A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

> **NCT06034002** · PHASE1 · RECRUITING · sponsor: **Incyte Corporation** · enrollment: 290 (estimated)

## Conditions studied

- Myeloproliferative Neoplasms

## Interventions

- **DRUG:** INCA033989
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT06034002
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-04
- **Primary completion:** 2028-10-29
- **Final completion:** 2028-10-29
- **Target enrollment:** 290 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06034002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06034002, "A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06034002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*